Jiguet-Jiglaire et al. demonstrated that low baseline plasma levels of MMP-9 were associated with a high response rate and a prolonged PFS and OS in patients with recurrent GBM treated with bevacizumab but not cytotoxic chemotherapy. The gene discussed is MMP9; the disease is glioblastoma.